medigraphic.com
ISSN 2594-1518 (Electronic)
ISSN 1405-0099 (Print)

2008, Number S1

<< Back Next >>

Cir Gen 2008; 30 (S1)

Surgical treatment of the gastrointestinal stromal tumors

Torres VS, Medrano GR, González RD

Language: Spanish
References: 29
Page: 27-31
PDF size: 128.78 Kb.


ABSTRACT

The traditional treatment for GISTs has been the resection of tumours; nevertheless, there are histopathologic, pharmacologic, and surgical factors which have made think the specialists in the possibility of administering systemic treatments (tyrosin kinase inhibitors) as a beneficial surgical option, compatible with surgery, among them the imatinib mesylate.


REFERENCES

  1. Nishida THS. Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol Pathol 2000; 15: 1293-1301.

  2. Tran T, Davila JA, ElSerag HB. The Epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1458 cases from 1992 to 2000. Am J Gatroenterol 2005; 100: 162-168.

  3. Tryggvason G, Gislason HG, Mafnusson MK, et al. Gastrointestinal stromal tumors in Iceland, 1990-2003; the Icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer 2005; 117: 289-293.

  4. Demetri GD, Benjamin R, et al. NCCN Task Force Report: management of patients with gastrointestinal stromal tumor update of the NCCN Clinical Practice Guidelines. J NCCN 2007; 5 (Suppl 2): 51-29.

  5. Goetsch WG, Bos SD, Breekveldt-Postma N, et al. Incidence of gastrointestinal stromal tumors in underestimated: results of a nation-wide study. Eur J Cancer 2005; 41: 2868-2872.

  6. Rubio J, Marcos-Gragera, Ortiz MR, et al. Incidence of gastrointestinal stromal tumors (GIST) In Girona, Spain. Eur J Cancer 2007; 43: 144-148.

  7. Nilson B, Bumming P, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical cause and prognostication in the preimatinib mesylate era a population based study in western Sweden. Cancer 2005; 103: 821-829.

  8. DeMatteo RP. The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-KIT), and inhibitor (STI571). Ann Surg Oncol 2002; 9: 831-9.

  9. Agaimy A, Wynsh PH, et al. Minute gastric sclerosing stromal tumors are common in adults an frequently show c-KIT mutations. Am J Surg Phatol 2007; 31: 113-120.

  10. Patel S, Benjamin R. Management of peritoneal and hepatic metastases from gastrointestinal stromal tumors. Surg Oncol 2000; 9: 67-70.

  11. Pierie JP, Choudry U, et al. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 2001; 136: 383-9.

  12. Miettinen M, Sobin LH, et al. Gastrointestinal stromal tumors of the stomach: a clinicophatologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Phatol 2005; 29: 52-68.

  13. Miettinen M, Sobin LH, et al. Gastrointestinal tumor of the jejunum and ileum: a clinical a clinicophatologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long term follow-up. Am J Surg Phatol 2006; 30: 477-489.

  14. Pérez EA, Livingstone AS, et al. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg 2006; 202: 623-629.

  15. Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Ann Oncol 2005; 16: 566-578.

  16. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23: 70-83.

  17. Demetri G, von Mehren M, Blajke C, el al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-80.

  18. Dow N, Giblen G, Sobin LH, et al. Gastrointestinal stromal tumors: differential diagnosis. Semin Diagn Pathol 2006; 23: 11-119.

  19. Chirieac LR, Trent JC, Steiner DM, et al. Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate. Cancer 2006; 107: 2237-2244.

  20. Kawanowa K, Sakuma Y, Sakuray S, el al. High incidence of microscopic gastrointestinal stromal tumor in the stomach. Hum Pathol 2006; 37: 1527-1535.

  21. Madeiros F, Corless CL, Duensing A, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Phatol 2004; 28: 889-894.

  22. Rothlin M, Schob O. Laparoscopic wedge resection for benign gastric tumors. Surg Endosc 2001; 15: 893-5.

  23. Pidhorecky I, Cheney RT, Kraybill WG, et al. Gastrointestinal stromal tumor: current diagnosis, biologic behavior, and management. Ann Surg Oncol 2000; 7: 705-12.

  24. Otani Y, Ohgami M, Igarashi N, et al. Laparoscopic wedge resection of gastric submucosal tumors. Surg Laparos Endos Percutn Thec 2000; 10: 19-23.

  25. Lehnert T. Gastrointestinal sarcoma (GIST a review of surgical management. Ann Chir Gynecol 1998; 87: 297-305.

  26. Margaret von Mehren, Watson JC, et al. Gastrointestinal tumors. Hematol Oncol Clin Am 2005; 19: 547-64.

  27. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-58.

  28. Eckardt AJ, Wassef W, et al. Diagnosis of subepithelial tumors in the GI tract. Endoscopy, EUS and histology: bronze, silver, and gold standard? Gastrointestinal Endoscopy 2005; 62: 209-212.

  29. Hirota S, Ohashi A, Nishida T, et al. Gain-of function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003; 125: 660-7.




2020     |     www.medigraphic.com